Replies to post #365 on BELLUS Health Inc (BLU)

[Power of Emouna]

Considering insiders loaded huge last few weeks i'm not worried! I'm following the money!! $BLU

Insider buys: Wow $631,619.90 was purchased by insiders in the last 3 week! Very telling!!

July 14, 2020 Bellini, Francesco 10,000 shares bought at $3.30 for total of $33,000.

July 13, 2020 Larochelle, Pierre 55,000 shares bought at $3.75 for a total of $206,250

July 06, 2020 Bellini, Francesco 56,187 shares bought at $2.70 for a total of $151,704.90

July 06, 2020 another purchase of Bellini, Francesco 50,000 shares bought at $2.73 for a total of $136,500

July 15, 2020 another purchase of Bellini, Francesco 41,666 shares. No registered price but average trading price for that day was $2.50/share. That's $104,165

Total of insider trades between July 06, 2020 and July 15, 2020 was $631,619.90

Check out the filings here! Click on Filings by transaction date to see them all.

https://m.canadianinsider.com/node/7?ticker=BLU

[Power of Emouna]

MUST WATCH

BELLUS Health Reports Full Year 2019 Financial Results

Cash Position: As of December 31, 2019, the Company had available cash, cash equivalents and short-term investments totalling C$116,884,000 (US$89,980,000), compared to C$48,906,000 (US$35,863,000) as at December 31, 2018.

Here is a direct link to the financial report:
https://ir.bellushealth.com/news-releases/news-release-details/bellus-health-reports-full-year-2019-financial-results-and


Solid company that admittedly had a setback on the FDA phase trial. CEO came out and stated they still know their product works but not at the limited threshold of the study. They will push for another phase 2 in 4th quarter and the stock will rebound hard much higher then $12 price before the crash if phase 2 is successful this time. We could see $20++ imo with a successful phase 2. Way oversold and undervalued down here. Go $BLU$

In the RELIEF trial, we observed data that we believe is competitive within the P2X3 class, including the reduction in cough frequency shown in patients with higher cough counts and a low taste effect. While we had hoped to see more response in the lower cough patients, BLU-5937 and other P2X3 antagonists may have the most benefit in patients with a greater disease burden,” said Roberto Bellini, President and Chief Executive Officer of BELLUS Health. “We believe the Phase 2 data support moving BLU-5937 forward into an adaptive Phase 2b trial enriched for higher cough count patients. We expect to begin this trial in the fourth quarter of 2020.”

https://www.otcmarkets.com/stock/BLU/news/story?e&id=1637916

[Up_Down]

I believe earnings are to be released 8/13 after market